PK, Safety & Tolerability of CyCol® Versus Sandimmune® in Healthy Subjects

NCT02130414 · clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
48
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Sigmoid Pharma